బ్రెయిన్ డిజార్డర్స్ & థెరపీ

నైరూప్య

Low-Dose, Off-Label Quetiapine Use, Metabolic Syndrome and Impaired Fasting Glucose in an Elderly Man: A Case Report

Margaret K. Hahn, Sylvia Gomes and Gary J. Remington

‘Atypical’ antipsychotics (AAPs), which have been associated with serious metabolic side effects, are increasingly being used for off-label indications other than psychosis, with little guidance available in this context as to risk of side effects, or monitoring.

Here we report on a case of emergent metabolic syndrome, in association with low-dose quetiapine used for insomnia in an elderly gentleman, which reversed following quetiapine discontinuation.